$1.03
+0.01 (+0.98%)
Open$1.03
Previous Close$1.02
Day High$1.03
Day Low$1.03
52W High$3.08
52W Low$0.96
Volume—
Avg Volume375.7K
Market Cap60.56M
P/E Ratio8.20
EPS$0.04
SectorBiotechnology
Analyst Ratings
Strong Sell
6 analysts
Price Target
+2,942.7% upside
Current
$1.03
$1.03
Target
$31.34
$31.34
$21.51
$31.34 avg
$48.77
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 64.65M | 60.04M | 30.93M |
| Net Income | 8.30M | 6.93M | -5,880,957 |
| Profit Margin | 12.8% | 12.2% | -19.0% |
| EBITDA | 6.11M | 5.39M | -8,827,347 |
| Free Cash Flow | — | — | -6,633,459 |
| Rev Growth | +7.7% | +7.7% | +18.4% |
| Debt/Equity | — | — | 0.33 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $294.45 | -0.18% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $467.06 | -0.22% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $167.95 | -1.05% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $542.62 | -0.81% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $951.19 | -0.86% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $156.65 | -2.00% | 7.7 | 20.98B |